Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Angelina Labib, Teresa Ju, Ashley Vander Does & Gil Yosipovitch. (2022) Immunotargets and Therapy for Prurigo Nodularis. ImmunoTargets and Therapy 11, pages 11-21.
Read now
Read now
Ludovica Toffoli, Eleonora Farinazzo, Enrico Zelin, Marina Agozzino, Caterina Dianzani, Nicola Di Meo, Katiuscia Nan, Iris Zalaudek & Claudio Conforti. (2022) Dupilumab as promising treatment for prurigo nodularis: current evidences. Journal of Dermatological Treatment 33:3, pages 1306-1311.
Read now
Read now
Svenja Müller, Thomas Bieber & Sonja Ständer. (2022) Therapeutic potential of biologics in prurigo nodularis. Expert Opinion on Biological Therapy 22:1, pages 47-58.
Read now
Read now
Articles from other publishers (21)
Yixin Shao, Duoqin Wang, Yiqi Zhu, Zijing Xiao, Taiyu Jin, Lisi Peng, Yanyun Shen & Hui Tang. (2023) Molecular mechanisms of pruritus in prurigo nodularis. Frontiers in Immunology 14.
Crossref
Crossref
Paola Facheris, Joel Correa Da Rosa, Angel D. Pagan, Michael Angelov, Ester Del Duca, Grace Rabinowitz, Pedro Jesús Gómez‐Arias, Camille Rothenberg‐Lausell, Yeriel D. Estrada, Swaroop Bose, Mashkura Chowdhury, Avner Shemer, Ana B. Pavel & Emma Guttman‐Yassky. (2023) Age of onset defines two distinct profiles of atopic dermatitis in adults. Allergy 78:8, pages 2202-2214.
Crossref
Crossref
Natalia Alkon, Frank P. Assen, Tamara Arnoldner, Wolfgang M. Bauer, Marco A. Medjimorec, Lisa E. Shaw, Katharina Rindler, Gregor Holzer, Philipp Weber, Wolfgang Weninger, Christian Freystätter, Sumanth Chennareddy, Tamar Kinaciyan, Matthias Farlik, Constanze Jonak, Johannes Griss, Christine Bangert & Patrick M. Brunner. (2023) Single-cell RNA sequencing defines disease-specific differences between chronic nodular prurigo and atopic dermatitis. Journal of Allergy and Clinical Immunology 152:2, pages 420-435.
Crossref
Crossref
Mikael Alsterholm, Axel Svedbom, Chris D. Anderson, Lena Holm Sommar, Lina U. Ivert, Anna Josefson, Laura Von Kobyletzki, Magnus Lindberg, Lena Lundeberg, Maria Lundqvist, Elisabet Nylander, MariHelen Sandström Falk, Alexander Shayesteh, Gunnthorunn Sigurdardottir, Andreas Sonesson, Åke Svensson, Marie Virtanen, Sophie Vrang, Carl-Fredrik Wahlgren, Maria Bradley & Emma K. Johansson. (2023) Establishment and Utility of SwedAD: A Nationwide Swedish Registry for Patients with Atopic Dermatitis Receiving Systemic Pharmacotherapy. Acta Dermato-Venereologica 103, pages adv7312.
Crossref
Crossref
Clara Muntaner-Virgili, Carlos Moreno-Vilchez, Clara Torrecilla-Vall-Llossera & Ignasi Figueras-Nart. (2023) Upadacitinib for prurigo nodularis: A case report. JAAD Case Reports.
Crossref
Crossref
Peng Cao, Wenjing Xu, Shuyi Jiang & Litao Zhang. (2023) Dupilumab for the treatment of prurigo nodularis: A systematic review. Frontiers in Immunology 14.
Crossref
Crossref
Cagdas Boyvadoglu & Huseyin Serhat Inaloz. (2023) Generalized prurigo nodularis with dramatic response to dupilumab treatment: A case report. World Journal of Dermatology 11:1, pages 1-6.
Crossref
Crossref
Clara Richter, Jürg Hafner, Manuel Schuermann, Matteo Tanadini, Nisia Trisconi, Peter Schmid-Grendelmeier, Thomas Kündig, Mirjam Nägeli, Marie-Charlotte Brüggen & Carole Guillet. (2023) Dupilumab for Chronic Prurigo: Case Series on Effectiveness, Safety, and Quality of Life. Dermatology 239:5, pages 811-817.
Crossref
Crossref
Zirui Gao, Yuanqing Dou, Pei Zhao, Caroline J Wang & Jianzhong Zhang. (2023) Successful Treatment of Prurigo Nodularis by Dupilumab: Report of 24 Patients. Dermatology 239:4, pages 658-663.
Crossref
Crossref
João Oliveira, Miguel Nogueira, Diana Pinto, Susana Machado, Ana Rita Araújo & Fernanda Teixeira. (2023) Role of dupilumab in pediatric prurigo nodularis: Beyond the skin. Pediatric Allergy and Immunology 34:1.
Crossref
Crossref
Varsha Parthasarathy, Karen Cravero, Junwen Deng, Zhe Sun, Sarah M. Engle, Autum N. Auxier, Nathan Hahn, Jonathan T. Sims, Angela J. Okragly, Martin P. Alphonse & Shawn G. Kwatra. (2022) Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: A cluster analysis. Frontiers in Medicine 9.
Crossref
Crossref
Nicole Edmonds, Patricia Zhao & Richard H Flowers. (2022) The use of dupilumab in patients with HIV. International Journal of STD & AIDS 33:14, pages 1165-1173.
Crossref
Crossref
Justin Greiwe, Richard Honsinger, Christopher Hvisdas, Derek K. Chu, David M. Lang, Richard Nicklas & Andrea J. Apter. (2022) Boxed Warnings and Off-Label Use of Allergy Medications: Risks, Benefits, and Shared Decision Making. The Journal of Allergy and Clinical Immunology: In Practice 10:12, pages 3057-3063.
Crossref
Crossref
Lai-San Wong & Yu-Ta Yen. (2022) Chronic Nodular Prurigo: An Update on the Pathogenesis and Treatment. International Journal of Molecular Sciences 23:20, pages 12390.
Crossref
Crossref
S. Ständer, G. Yosipovitch, J.‐P. Lacour, F.J. Legat, C. Paul, A. Reich, K. Chaouche, F. Ahmad & C. Piketty. (2022) Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances. Journal of the European Academy of Dermatology and Venereology 36:10, pages 1820-1825.
Crossref
Crossref
M. Gael, T. Adam, M. Mariano‐Bourin & A.‐C. Bursztejn. (2022) Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors. Journal of the European Academy of Dermatology and Venereology 36:9, pages 1541-1551.
Crossref
Crossref
Javier Gil‐Lianes, Constanza Riquelme‐Mc Loughlin & Jose Manuel MascaróJr.Jr.. (2022) Reactive perforating collagenosis successfully treated with dupilumab. Australasian Journal of Dermatology 63:3, pages 398-400.
Crossref
Crossref
Claudia Zeidler, Manuel Pedro Pereira & Sonja Ständer. (2022) Update zur Therapie der chronischen PrurigoUpdate on the treatment of chronic prurigo. Die Dermatologie 73:8, pages 614-619.
Crossref
Crossref
E. Weisshaar, J.C. Szepietowski, J.D. Bernhard, H. Hait, F.J. Legat, L. Nattkemper, A. Reich, B. Sadoghi, T.R. Sciascia, C. Zeidler, G. Yosipovitch & S. Ständer. (2021) Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open‐label extension phase. Journal of the European Academy of Dermatology and Venereology 36:3, pages 453-461.
Crossref
Crossref
Regina Fölster-Holst, Rahel Reimer, Claudia Neumann, Erhardt Proksch, Elke Rodriguez, Stephan Weidinger, Mohamad Goldust, Eckhard Hanisch, Stephan Dähnhardt-Pfeiffer & Sandra Freitag-Wolf. (2021) Comparison of Epidermal Barrier Integrity in Adults with Classic Atopic Dermatitis, Atopic Prurigo and Non-Atopic Prurigo Nodularis. Biology 10:10, pages 1008.
Crossref
Crossref
Satoshi Takeuchi, Keiichi Inoue, Keisuke Kuretake, Mari Kiyomatsu‐Oda & Masutaka Furue. (2021) Dupilumab shows slow, steady effectiveness for intractable prurigo in patients with atopic dermatitis. The Journal of Dermatology 48:5, pages 638-644.
Crossref
Crossref